CTI Demands LifeLine BioTechnologies Cease Unauthorized Use of CTI's Name
in All Communications With Wall Street, the Media and the Industry
OGDEN, Utah, Nov. 5 /PRNewswire/ -- Computerized Thermal Imaging, Inc. (OTC Bulletin Board: COII - news; CTI), a leader in the development of thermal imaging for the diagnosis of malignant breast cancer tumors, said today that its general counsel has sent a formal request to the management of LifeLine BioTechnologies demanding that LifeLine cease using CTI's name in its press releases, conference calls and other communications with the investment community and public at large.
CTI's president, David A. Packer said, "There have been a number of instances in which LifeLine has used our Company's name in its press releases without our consent. LifeLine seems to be trying to take advantage of our good name, reputation and our leading role in the development of breast cancer detection technology to expand the visibility of their company and its food supplement products by deliberately manipulating the Internet news delivery mechanisms by referencing CTI's breast cancer technology. Their actions have created confusion and conveyed a false impression to some that we have somehow aligned ourselves with this nutritional food company. Nothing could be further from the truth."
"In addition, LifeLine made statements regarding CTI and our technology in their recent conference call that were false and misleading. They claim to be an alternative to CTI while their statements make it clear that they have little or no knowledge of us, our technology or our advanced stage of product development and approval. We have therefore informed the management of LifeLine and its public relations firm to immediately cease the unauthorized use of CTI's name in any public communications. In the event that LifeLine fails to comply with our request, we intend to take legal action,'' Packer added.
CTI's technology uses a sophisticated heat sensitive camera to record an image of heat waves produced by breast tissue. This image is processed by a proprietary computer program that is designed to recognize and differentiate the distinct heat signatures of malignant and benign breast tumors. The procedure is painless and requires no exposure to radiation or breast compression. Clinical trials are currently underway at a number of leading cancer research centers and hospitals.
Computerized Thermal Imaging, Inc. develops and deploys thermal imaging and associated technologies for use in the enhancement of medical screening, diagnosis and patient management. More information about CTI can be found on the Internet at www.cti-net.com or by calling CTI Public Affairs at 801-776-4700.
Except for historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In addition to the factors set forth above, other important factors that could cause actual results to differ materially include, but are not limited to technical risks associated with new technology development, government regulatory approvals or continued working capital. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings. Copies of these filings may be obtained by contacting the Company or the SEC.
SOURCE: Computerized Thermal Imaging, Inc.
[BACK]
|
